Who we are

We are a team of trailblazing scientists, data engineers and drug developers finding drugs that alter the course of tough-to-treat diseases with minimal toxicity

Biology

RNA biology & RNA-guided mechanisms of gene regulation
Innovative CRISPR applications
Single cell functional genomics

Artificial Intelligence

Deep learning to decode gene signaling networks & quantify wide-scale single cell gene modulation
Human-centric, multi-omics data generation and analytics throughout disease progression
Novel applications across multiple disease verticals

Drug Development

Target ID & validation based on translatable therapeutic metrics
Drug development from target to clinic
Novel preclinical models

Meet The Team

Leadership

Chun-Hao Huang, PhD

CEO & Co-Founder

Christine Du, MBA

CBO & Co-Founder

Jeff Whitten, PhD

CSO

Advisors

Jennifer Doudna, PhD

Frank McCormick, PhD

Matthew Rabinowitz, PhD

Cole Trapnell, PhD

Spencer Knight, PhD

Our Investors

Our success is driven not only by our innovation but also by the strategic partnerships we've forged with some of the world's most accomplished investors